Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fumagillin→

Fumagillin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23110-15-8
Molecular formula
C26H34O7
Molecular weight
458.55 g/mol
Drug class
Antimicrosporidial antibioticmethionine aminopeptidase-2 (MetAP2) inhibitor
Mechanism of action
Inhibits methionine aminopeptidase 2, an enzyme required for protein maturation and microsporidial proliferation. MetAP2 inhibition also accounts for antiangiogenic activity observed in other experimental settings.
Indications / reported uses
  • Treatment of intestinal microsporidiosis caused by Enterocytozoon bieneusi in selected immunocompromised patients under specialist guidance.
  • Topical compounded fumagillin has been used for ocular microsporidial infection; systemic and topical availability is limited and jurisdiction-specific.

Sources: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/microsporidiosis · https://www.nejm.org/doi/full/10.1056/NEJMoa012924 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fumagillin Environmental Risk Assessment (ERA) (the Fumagillin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.